{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:24:31Z","timestamp":1793147071017,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 T32 CA101642 02"],"award-info":[{"award-number":["5 T32 CA101642 02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2P50 CA109298"],"award-info":[{"award-number":["2P50 CA109298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11864-018-0572-7","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T06:14:44Z","timestamp":1542262484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Katherine C.","family":"Kurnit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"issue":"1","key":"572_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. \n                      https:\/\/doi.org\/10.3322\/caac.21442\n                      \n                    .","journal-title":"CA Cancer J Clin"},{"key":"572_CR2","unstructured":"Network NCC. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 2.2018). \n                      https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf\n                      \n                    . Accessed 29 June 2018."},{"key":"572_CR3","doi-asserted-by":"publisher","first-page":"362):362\u00a0ps17","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, O\u2019Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8:362):362\u00a0ps17. \n                      https:\/\/doi.org\/10.1126\/scitranslmed.aaf9246\n                      \n                    .","journal-title":"Sci Transl Med"},{"issue":"1","key":"572_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","volume":"9","author":"GE Ronson","year":"2018","unstructured":"Ronson GE, Piberger AL, Higgs MR, Olsen AL, Stewart GS, McHugh PJ, et al. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat Commun. 2018;9(1):746. \n                      https:\/\/doi.org\/10.1038\/s41467-018-03159-2\n                      \n                    .","journal-title":"Nat Commun"},{"issue":"12","key":"572_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/jco.2014.58.8848","volume":"33","author":"CL Scott","year":"2015","unstructured":"Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015;33(12):1397\u2013406. \n                      https:\/\/doi.org\/10.1200\/jco.2014.58.8848\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"21","key":"572_CR6","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.can-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399. \n                      https:\/\/doi.org\/10.1158\/0008-5472.can-12-2753\n                      \n                    .","journal-title":"Cancer Res"},{"issue":"2","key":"572_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.mrrev.2003.07.001","volume":"566","author":"A Dudas","year":"2004","unstructured":"Dudas A, Chovanec M. DNA double-strand break repair by homologous recombination. Mutat Res. 2004;566(2):131\u201367. \n                      https:\/\/doi.org\/10.1016\/j.mrrev.2003.07.001\n                      \n                    .","journal-title":"Mutat Res"},{"issue":"16","key":"572_CR8","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.can-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109\u201315. \n                      https:\/\/doi.org\/10.1158\/0008-5472.can-06-0140\n                      \n                    .","journal-title":"Cancer Res"},{"issue":"15","key":"572_CR9","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.ccr-16-2615","volume":"23","author":"S Lheureux","year":"2017","unstructured":"Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, et al. Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization. Clin Cancer Res. 2017;23(15):4086\u201394. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2615\n                      \n                    .","journal-title":"Clin Cancer Res"},{"key":"572_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","volume":"60","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer (Oxford, England: 1990). 2016;60:49\u201358. \n                      https:\/\/doi.org\/10.1016\/j.ejca.2016.03.005\n                      \n                    .","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"572_CR11","doi-asserted-by":"publisher","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315. \n                      https:\/\/doi.org\/10.1038\/nature10166\n                      \n                    .","DOI":"10.1038\/nature10166"},{"issue":"3","key":"572_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/jco.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germ line BRCA1\/2 mutation. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(3):244\u201350. \n                      https:\/\/doi.org\/10.1200\/jco.2014.56.2728\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"572_CR13","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.ccr-15-0887","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA Approval summary: olaparib monotherapy in patients with deleterious germ line BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257\u201361. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-0887\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"15","key":"572_CR14","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1078-0432.ccr-16-2796","volume":"23","author":"R Kristeleit","year":"2017","unstructured":"Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germ line BRCA1\/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095\u2013106. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2796\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"1","key":"572_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(16)30559-9\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"2","key":"572_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","volume":"147","author":"AM Oza","year":"2017","unstructured":"\u2022 Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germ line or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267\u201375. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.022\n                      \n                     The integrated analysis of two phase II studies of rucaparib in recurrent ovarian cancer patients with BRCA mutations. This provided the basis for the rucaparib FDA approval.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"572_CR17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/s1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882\u201392. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(13)70240-7\n                      \n                    .","journal-title":"Lancet Oncol"},{"key":"572_CR18","doi-asserted-by":"crossref","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven NG, Fleming GF, et al. QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received \u2265\u20093 prior chemotherapy regimens. J Clin Oncol. 2018;36(15_suppl):5514.","DOI":"10.1200\/JCO.2018.36.15_suppl.5514"},{"issue":"3","key":"572_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"RL Coleman","year":"2015","unstructured":"Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germ line BRCA1 or BRCA2 mutation\u2014an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol. 2015;137(3):386\u201391. \n                      https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.042\n                      \n                    .","journal-title":"Gynecol Oncol"},{"issue":"22","key":"572_CR20","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"\u2022\u2022 Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1611310\n                      \n                     The phase III study of niraparib in platinum-sensitive, recurrent ovarian cancer patients. This study served as the basis for the FDA approval.","journal-title":"N Engl J Med"},{"issue":"15","key":"572_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1105535\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"8","key":"572_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/s1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(14)70228-1\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"11","key":"572_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(16)30376-x","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579\u201389. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(16)30376-x\n                      \n                    .","journal-title":"Lancet Oncol"},{"issue":"11","key":"572_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.348","volume":"115","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016;115(11):1313\u201320. \n                      https:\/\/doi.org\/10.1038\/bjc.2016.348\n                      \n                    .","journal-title":"Br J Cancer"},{"issue":"9","key":"572_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/s1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"\u2022\u2022 Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(17)30469-2\n                      \n                     The phase III study of olaparib in platinum-sensitive, recurrent ovarian cancer patients with BRCA mutations. This study served as the basis for the FDA approval.","journal-title":"Lancet Oncol"},{"issue":"10106","key":"572_CR26","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/s0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"\u2022\u2022 Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;390(10106):1949\u201361. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(17)32440-6\n                      \n                     The phase III study of rucaparib in platinum-sensitive, recurrent ovarian cancer patients. This study served as the basis for the FDA approval.","journal-title":"Lancet (London, England)"},{"key":"572_CR27","doi-asserted-by":"crossref","unstructured":"Bell-McGuinn KM, Brady WE, Schilder RJ, Fracasso PM, Moore KN, Walker JL, et al. A phase I study of continuous veliparib in combination with IV carboplatin\/paclitaxel or IV\/IP paclitaxel\/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study. J Clin Oncol. 2015;33(15_suppl):5507.","DOI":"10.1200\/jco.2015.33.15_suppl.5507"},{"issue":"11","key":"572_CR28","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/cas.13381","volume":"108","author":"S Nishio","year":"2017","unstructured":"Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, et al. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci. 2017;108(11):2213\u201320. \n                      https:\/\/doi.org\/10.1111\/cas.13381\n                      \n                    .","journal-title":"Cancer Sci"},{"issue":"15_suppl","key":"572_CR29","doi-asserted-by":"publisher","first-page":"TPS5616-TPS","DOI":"10.1200\/jco.2014.32.15_suppl.tps5616","volume":"32","author":"KN Moore","year":"2014","unstructured":"Moore KN, DiSilvestro P, Lowe ES, Garnett S, Pujade-Lauraine E. SOLO1 and SOLO2: randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1\/2 mutation (BRCAm). J Clin Oncol. 2014;32(15_suppl):TPS5616-TPS. \n                      https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.tps5616\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"4","key":"572_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/bjc.2014.345","volume":"111","author":"G Del Conte","year":"2014","unstructured":"Del Conte G, Sessa C, von Moos R, Vigano L, Digena T, Locatelli A, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014;111(4):651\u20139. \n                      https:\/\/doi.org\/10.1038\/bjc.2014.345\n                      \n                    .","journal-title":"Br J Cancer"},{"issue":"7","key":"572_CR31","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.ccr-14-2565","volume":"21","author":"S Kummar","year":"2015","unstructured":"Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015;21(7):1574\u201382. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2565\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"4","key":"572_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1158\/1078-0432.ccr-17-1590","volume":"24","author":"AE Wahner Hendrickson","year":"2018","unstructured":"Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, et al. A phase I clinical trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors. Clin Cancer Res. 2018;24(4):744\u201352. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-1590\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"1","key":"572_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"\u2022 Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87\u201397. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(14)71135-0\n                      \n                     One of the first phase II trials evaluating the combination of a PARP inhibitor with standard of care chemotherapy.","journal-title":"Lancet Oncol"},{"issue":"6","key":"572_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1158\/1078-0432.ccr-16-1546","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, et al. Sequence-specific pharmacokinetic and pharmacodynamic phase I\/Ib study of olaparib tablets and carboplatin in women\u2019s cancer. Clin Cancer Res. 2017;23(6):1397\u2013406. \n                      https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-1546\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"572_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/annonc\/mdw672","volume":"28","author":"UA Matulonis","year":"2017","unstructured":"Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28(3):512\u20138. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdw672\n                      \n                    .","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"572_CR36","doi-asserted-by":"publisher","first-page":"mdx367.025-mdx3","DOI":"10.1093\/annonc\/mdx367.025","volume":"28","author":"S Westin","year":"2017","unstructured":"Westin S, Litton J, Williams R, Soliman P, Frumovitz M, Schmeler K, et al. 391P Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer. Ann Oncol. 2017;28(suppl_5):mdx367.025-mdx367.025. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdx367.025\n                      \n                    .","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"572_CR37","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1200\/JCO.2018.36.15_suppl.5504","volume":"36","author":"SN Westin","year":"2018","unstructured":"Westin SN, Litton JK, Williams RA, Shepherd CJ, Brugger W, Pease EJ, et al. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1\/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. J Clin Oncol. 2018;36(15_suppl):5504. \n                      https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5504\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"11","key":"572_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/s1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"\u2022 Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet Oncology. 2014;15(11):1207\u201314. \n                      https:\/\/doi.org\/10.1016\/s1470-2045(14)70391-2\n                      \n                     One of the most promising published clinical trials of the combination of a PARP inhibitor and a novel agent. The combination had more notable improvement in efficacy in BRCA wild type patients.","journal-title":"The Lancet Oncology"},{"issue":"15_suppl","key":"572_CR39","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1200\/JCO.2017.35.15_suppl.5535","volume":"35","author":"JF Liu","year":"2017","unstructured":"Liu JF, Barry WT, Birrer MJ, J-m L, Buckanovich RJ, Fleming GF, et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2017;35(15_suppl):5535. \n                      https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.5535\n                      \n                    .","journal-title":"J Clin Oncol"},{"key":"572_CR40","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, Holloway RW, et al. TOPACIO\/Keynote-162 (NCT02657889): A phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort. J Clin Oncol. 2018;36(15_suppl):106.","DOI":"10.1200\/JCO.2018.36.15_suppl.106"},{"key":"572_CR41","doi-asserted-by":"crossref","unstructured":"Drew Y, De Jonge M, Hong SH, Park YH, Wolfer A, Brown J et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germ line BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer; March 26, 2018; New Orleans, Louisiana2018.","DOI":"10.1016\/j.ygyno.2018.04.555"},{"issue":"19","key":"572_CR42","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1200\/jco.2016.72.1340","volume":"35","author":"JM Lee","year":"2017","unstructured":"Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1\u20133 inhibitor cediranib in women\u2019s cancers: a dose-escalation, phase I study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(19):2193\u2013202. \n                      https:\/\/doi.org\/10.1200\/jco.2016.72.1340\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"suppl_6","key":"572_CR43","doi-asserted-by":"publisher","first-page":"1103TiP-TiP","DOI":"10.1093\/annonc\/mdw378.56","volume":"27","author":"S Domchek","year":"2016","unstructured":"Domchek S, Bang YJ, Coukos G, Kobayashi K, Baker N, McMurtry E, et al. MEDIOLA: A phase I\/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours. Annals of Oncology. 2016;27(suppl_6):1103TiP-TiP. \n                      https:\/\/doi.org\/10.1093\/annonc\/mdw378.56\n                      \n                    .","journal-title":"Annals of Oncology"},{"key":"572_CR44","doi-asserted-by":"publisher","unstructured":"Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017;9(392). \n                      https:\/\/doi.org\/10.1126\/scitranslmed.aal5148\n                      \n                    .","DOI":"10.1126\/scitranslmed.aal5148"},{"key":"572_CR45","doi-asserted-by":"crossref","unstructured":"Kaufmann SH, Hendrickson AEW, Harrell MI, Menefee ME, Tanner EJ, Mutch DG et al. Abstract IS04: PARP inhibitor combinations for the treatment of ovarian cancer. Clin Cancer Res. 2017;23(11_Suppl):IS04.","DOI":"10.1158\/1557-3265.OVCASYMP16-IS04"},{"key":"572_CR46","doi-asserted-by":"crossref","unstructured":"Wilson AJ, Thompson J, Osman A, Saskowski J, Khabele DK. Abstract 5056: The bromodomain inhibitor JQ1 sensitizes homologous recombination proficient ovarian cancer cells to the PARP inhibitor olaparib. Cancer Res. 2017;77(13_Suppl):5056.","DOI":"10.1158\/1538-7445.AM2017-5056"},{"issue":"67","key":"572_CR47","doi-asserted-by":"publisher","first-page":"111026","DOI":"10.18632\/oncotarget.22195","volume":"8","author":"E Brill","year":"2017","unstructured":"Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget. 2017;8(67):111026\u201340. \n                      https:\/\/doi.org\/10.18632\/oncotarget.22195\n                      \n                    .","journal-title":"Oncotarget"},{"issue":"30","key":"572_CR48","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1038\/onc.2013.352","volume":"33","author":"J Michels","year":"2014","unstructured":"Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene. 2014;33(30):3894\u2013907. \n                      https:\/\/doi.org\/10.1038\/onc.2013.352\n                      \n                    .","journal-title":"Oncogene"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-018-0572-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-018-0572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T18:09:23Z","timestamp":1589738963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-018-0572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1007\/s11864-018-0572-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"15 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Katherine Kurnit declares that she has no conflict of interest.Robert L. Coleman has received research funding through grants from the National Institutes of Health (NIH), the Gateway Fondation, and the V Foundation; has also received research support from AstraZeneca, Merck, Clovis, Genmab, Roche\/Genentech, and Janssen; and has received compensation from AstraZeneca, Tesaro, Medivation, Clovis, GamaMabs, Genmab, Roche\/Genentech, Janssen, Agenus, Regeneron, and OncoQuest for service as a consultant.Shannon N. Westin has received research funding through grants from the NIH and the Andrew Sabin Family Fellowship; has also received research support from AstraZeneca, Tesaro, and Cotinga Pharmaceuticals; and has received compensation from AstraZeneca, Merck, Tesaro, Medivation, Clovis, Casdin Capital, Ovation, and Roche\/Genentech for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"1"}}